ANRO:NYE-Alto Neuroscience, Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 11.89

Change

-1.40 (-10.53)%

Market Cap

USD 0.37B

Volume

0.35M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California. Address: 369 South San Antonio Road, Los Altos, CA, United States, 94022

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

+1.74 (+1.41%)

USD 609.93B
BHVN Biohaven Pharmaceutical Holdin..

-0.90 (-1.96%)

USD 4.34B
RCUS Arcus Biosciences Inc

-0.11 (-0.70%)

USD 1.51B
NUVB Nuvation Bio Inc

-0.08 (-2.92%)

USD 1.03B
DNA Ginkgo Bioworks Holdings

+0.24 (+3.07%)

USD 0.45B
ADCT ADC Therapeutics SA

-0.03 (-0.97%)

USD 0.29B
CYBN Cybin Inc

+0.37 (+3.84%)

USD 0.15B
ANVS Annovis Bio Inc

+0.01 (+0.13%)

USD 0.10B
ARMP Armata Pharmaceuticals Inc

-0.15 (-6.36%)

USD 0.09B
PLX Protalix Biotherapeutics Inc

-0.04 (-3.57%)

USD 0.08B

ETFs Containing ANRO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.37B 82% B 44% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector